Table 2 Trial groups and timeline of vaccination, specimen collection, and measurement of endpoints
Group | |||
|---|---|---|---|
Age | 3+0 Acquisition (n = 392) Immunogenicity (n = 112) | 1+1 Acquisition (n = 196) Immunogenicity-YF/PCV co-administration (n = 112) | 1+1 YFseparate Acquisition (n = 196) Immunogenicity-YF/PCV separate administration (n = 112) |
6 wk | PCV13 NPS (n = 392) | PCV13 NPS (n = 196) | PCV13 NPS (n = 196) |
10 wk | PCV13 | Blood IgG (n = 112) OPA (n = 60) | |
14 wk | PCV13 | ||
18 wk | Blood IgG (n = 112) OPA (n = 60) | ||
6 mo | NPS (n = 392) | NPS (n = 196) | NPS (n = 196) |
9 mo | YF Blood IgG (n = 112) NPS (n = 392) | YF & PCV13 Blood IgG (n = 56) NPS (n = 196) | PCV13 Blood IgG (n = 56) NPS (n = 196) |
10 mo | Blood YFNA (n = 112) IgG (n = 112) OPA (n = 60) NPS (n = 392) | Blood YFNA (n = 112) IgG (n = 112) OPA (n = 60) NPS (n = 196) | YF Blood IgG (n = 112) NPS (n = 196) |
11 mo | NPS (n = 392) | NPS (n = 196) | Blood YFNA (n=112) NPS (n=196) |
12 mo | NPS (n = 392) | NPS (n=196) | NPS (n=196) |
13 mo | NPS (n = 392) | NPS (n=196) | NPS (n=196) |
14 mo | NPS (n = 392) | NPS (n=196) | NPS (n=196) |
18 mo | Blood IgG (n = 112) OPA (n = 60) NPS (n = 392) | Blood IgG (n = 112) OPA (n = 60) NPS (n = 196) | NPS (n=196) |